Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 10/2010

01-10-2010 | Original Paper

Induction of MKP-1 prevents the cytotoxic effects of PI3K inhibition in hilar cholangiocarcinoma cells

Authors: Kawin Leelawat, Wandee Udomchaiprasertkul, Siriluck Narong, Surang Leelawat

Published in: Journal of Cancer Research and Clinical Oncology | Issue 10/2010

Login to get access

Abstract

Purpose

Hilar cholangiocarcinoma (Klatskin tumor) is one of the most difficult cancers to treat. We demonstrate activation of phosphoinositide-3-kinase (PI3K)/Akt signaling, which is a critical pathway for cell survival, in hilar cholangiocarcinoma cells. However, inhibition of PI3K has little effect on hilar cholangiocarcinoma cell survival. In this study, we investigated the mechanism by which hilar cholangiocarcinoma cells resist PI3K inhibitors.

Methods

Human hilar cholangiocarcinoma cells KKU-100 were treated with PI3K inhibitors, and cell viability and apoptosis assays were performed. The expression of a MAPK phosphatase (MKP-1) that contributes to cancer cell survival in response to multiple stress stimuli was assayed by quantitative real-time RT-PCR and western blotting. In addition, the effects of the MKP-1 inhibitor were studied in KKU-100 cells treated with PI3K inhibitors.

Results

Incubation of KKU-100 cells with PI3K inhibitors resulted in increased expression of MKP-1. Furthermore, we found that inhibition of MKP-1 using siRNA silencing sensitized KKU-100 cells to PI3K inhibitor-induced apoptosis via increased phosphorylation of p38 MAPK.

Conclusions

These results indicate that concurrent inhibition of PI3K and MKP-1 induces apoptosis in KKU-100 cells. Simultaneous targeting of the PI3K pathway and MKP-1 may be a useful approach to improve therapies directed against hilar cholangiocarcinoma.
Literature
go back to reference Boutros T, Chevet E, Metrakos P (2008) Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase regulation: roles in cell growth, death, and cancer. Pharmacol Rev 60(3):261–310CrossRefPubMed Boutros T, Chevet E, Metrakos P (2008) Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase regulation: roles in cell growth, death, and cancer. Pharmacol Rev 60(3):261–310CrossRefPubMed
go back to reference Chattopadhyay S, Machado-Pinilla R, Manguan-Garcia C, Belda-Iniesta C, Moratilla C, Cejas P, Fresno-Vara JA, de Castro-Carpeno J, Casado E, Nistal M, Gonzalez-Baron M, Perona R (2006) MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer. Oncogene 25(23):3335–3345CrossRefPubMed Chattopadhyay S, Machado-Pinilla R, Manguan-Garcia C, Belda-Iniesta C, Moratilla C, Cejas P, Fresno-Vara JA, de Castro-Carpeno J, Casado E, Nistal M, Gonzalez-Baron M, Perona R (2006) MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer. Oncogene 25(23):3335–3345CrossRefPubMed
go back to reference Cheng B, Rhodus NL, Williams B, Griffin RJ (2004) Detection of apoptotic cells in whole saliva of patients with oral premalignant and malignant lesions: a preliminary study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 97(4):465–470CrossRefPubMed Cheng B, Rhodus NL, Williams B, Griffin RJ (2004) Detection of apoptotic cells in whole saliva of patients with oral premalignant and malignant lesions: a preliminary study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 97(4):465–470CrossRefPubMed
go back to reference Chung JY, Hong SM, Choi BY, Cho H, Yu E, Hewitt SM (2009) The expression of phospho-AKT, phospho-mTOR, and PTEN in extrahepatic cholangiocarcinoma. Clin Cancer Res 15(2):660–667CrossRefPubMed Chung JY, Hong SM, Choi BY, Cho H, Yu E, Hewitt SM (2009) The expression of phospho-AKT, phospho-mTOR, and PTEN in extrahepatic cholangiocarcinoma. Clin Cancer Res 15(2):660–667CrossRefPubMed
go back to reference Cortes-Sempere M, Chattopadhyay S, Rovira A, Rodriguez-Fanjul V, Belda-Iniesta C, Tapia M, Cejas P, Machado-Pinilla R, Manguan-Garcia C, Sanchez-Perez I, Nistal M, Moratilla C, Castro-Carpeno JD, Gonzalez-Baron M, Albanell J, Perona R (2009) MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3 K inhibitors to cisplatin in non-small cell lung cancer. Cancer Lett 286(2):206–216CrossRefPubMed Cortes-Sempere M, Chattopadhyay S, Rovira A, Rodriguez-Fanjul V, Belda-Iniesta C, Tapia M, Cejas P, Machado-Pinilla R, Manguan-Garcia C, Sanchez-Perez I, Nistal M, Moratilla C, Castro-Carpeno JD, Gonzalez-Baron M, Albanell J, Perona R (2009) MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3 K inhibitors to cisplatin in non-small cell lung cancer. Cancer Lett 286(2):206–216CrossRefPubMed
go back to reference Franklin CC, Srikanth S, Kraft AS (1998) Conditional expression of mitogen-activated protein kinase phosphatase-1, MKP-1, is cytoprotective against UV-induced apoptosis. Proc Natl Acad Sci USA 95(6):3014–3019CrossRefPubMed Franklin CC, Srikanth S, Kraft AS (1998) Conditional expression of mitogen-activated protein kinase phosphatase-1, MKP-1, is cytoprotective against UV-induced apoptosis. Proc Natl Acad Sci USA 95(6):3014–3019CrossRefPubMed
go back to reference Givant-Horwitz V, Davidson B, Goderstad JM, Nesland JM, Trope CG, Reich R (2004) The PAC-1 dual specificity phosphatase predicts poor outcome in serous ovarian carcinoma. Gynecol Oncol 93(2):517–523CrossRefPubMed Givant-Horwitz V, Davidson B, Goderstad JM, Nesland JM, Trope CG, Reich R (2004) The PAC-1 dual specificity phosphatase predicts poor outcome in serous ovarian carcinoma. Gynecol Oncol 93(2):517–523CrossRefPubMed
go back to reference Keyse SM (2008) Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev 27(2):253–261CrossRefPubMed Keyse SM (2008) Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev 27(2):253–261CrossRefPubMed
go back to reference Kim GS, Choi YK, Song SS, Kim WK, Han BH (2005) MKP-1 contributes to oxidative stress-induced apoptosis via inactivation of ERK1/2 in SH-SY5Y cells. Biochem Biophys Res Commun 338(4):1732–1738CrossRefPubMed Kim GS, Choi YK, Song SS, Kim WK, Han BH (2005) MKP-1 contributes to oxidative stress-induced apoptosis via inactivation of ERK1/2 in SH-SY5Y cells. Biochem Biophys Res Commun 338(4):1732–1738CrossRefPubMed
go back to reference Leelawat K, Leelawat S, Narong S, Hongeng S (2007) Roles of the MEK1/2 and AKT pathways in CXCL12/CXCR4 induced cholangiocarcinoma cell invasion. World J Gastroenterol 13(10):1561–1568PubMed Leelawat K, Leelawat S, Narong S, Hongeng S (2007) Roles of the MEK1/2 and AKT pathways in CXCL12/CXCR4 induced cholangiocarcinoma cell invasion. World J Gastroenterol 13(10):1561–1568PubMed
go back to reference Leelawat K, Narong S, Udomchaiprasertkul W, Leelawat S, Tungpradubkul S (2009) Inhibition of PI3 K increases oxaliplatin sensitivity in cholangiocarcinoma cells. Cancer Cell Int 8(9):3CrossRef Leelawat K, Narong S, Udomchaiprasertkul W, Leelawat S, Tungpradubkul S (2009) Inhibition of PI3 K increases oxaliplatin sensitivity in cholangiocarcinoma cells. Cancer Cell Int 8(9):3CrossRef
go back to reference Lin YW, Chuang SM, Yang JL (2003) ERK1/2 achieves sustained activation by stimulating MAPK phosphatase-1 degradation via the ubiquitin–proteasome pathway. J Biol Chem 278(24):21534–21541CrossRefPubMed Lin YW, Chuang SM, Yang JL (2003) ERK1/2 achieves sustained activation by stimulating MAPK phosphatase-1 degradation via the ubiquitin–proteasome pathway. J Biol Chem 278(24):21534–21541CrossRefPubMed
go back to reference Mazhar D, Stebbing J, Bower M (2006) Chemotherapy for advanced cholangiocarcinoma: what is standard treatment? Future Oncol 2(4):509–514CrossRefPubMed Mazhar D, Stebbing J, Bower M (2006) Chemotherapy for advanced cholangiocarcinoma: what is standard treatment? Future Oncol 2(4):509–514CrossRefPubMed
go back to reference Miller AL, Webb MS, Copik AJ, Wang Y, Johnson BH, Kumar R, Thompson EB (2005) p38 Mitogen-activated protein kinase (MAPK) is a key mediator in glucocorticoid-induced apoptosis of lymphoid cells: correlation between p38 MAPK activation and site-specific phosphorylation of the human glucocorticoid receptor at serine 211. Mol Endocrinol 19(6):1569–1583CrossRefPubMed Miller AL, Webb MS, Copik AJ, Wang Y, Johnson BH, Kumar R, Thompson EB (2005) p38 Mitogen-activated protein kinase (MAPK) is a key mediator in glucocorticoid-induced apoptosis of lymphoid cells: correlation between p38 MAPK activation and site-specific phosphorylation of the human glucocorticoid receptor at serine 211. Mol Endocrinol 19(6):1569–1583CrossRefPubMed
go back to reference Obata T, Brown GE, Yaffe MB (2000) MAP kinase pathways activated by stress: the p38 MAPK pathway. Crit Care Med 28(4 Suppl):67–77CrossRef Obata T, Brown GE, Yaffe MB (2000) MAP kinase pathways activated by stress: the p38 MAPK pathway. Crit Care Med 28(4 Suppl):67–77CrossRef
go back to reference Orlowski RZ, Small GW, Shi YY (2002) Evidence that inhibition of p44/42 mitogen-activated protein kinase signaling is a factor in proteasome inhibitor-mediated apoptosis. J Biol Chem 277(31):27864–27871CrossRefPubMed Orlowski RZ, Small GW, Shi YY (2002) Evidence that inhibition of p44/42 mitogen-activated protein kinase signaling is a factor in proteasome inhibitor-mediated apoptosis. J Biol Chem 277(31):27864–27871CrossRefPubMed
go back to reference Rojo F, Gonzalez-Navarrete I, Bragado R, Dalmases A, Menendez S, Cortes-Sempere M, Suarez C, Oliva C, Servitja S, Rodriguez-Fanjul V, Sanchez-Perez I, Campas C, Corominas JM, Tusquets I, Bellosillo B, Serrano S, Perona R, Rovira A, Albanell J (2009) Mitogen-activated protein kinase phosphatase-1 in human breast cancer independently predicts prognosis and is repressed by doxorubicin. Clin Cancer Res 15(10):3530–3539CrossRefPubMed Rojo F, Gonzalez-Navarrete I, Bragado R, Dalmases A, Menendez S, Cortes-Sempere M, Suarez C, Oliva C, Servitja S, Rodriguez-Fanjul V, Sanchez-Perez I, Campas C, Corominas JM, Tusquets I, Bellosillo B, Serrano S, Perona R, Rovira A, Albanell J (2009) Mitogen-activated protein kinase phosphatase-1 in human breast cancer independently predicts prognosis and is repressed by doxorubicin. Clin Cancer Res 15(10):3530–3539CrossRefPubMed
go back to reference Sano T, Shimada K, Sakamoto Y, Ojima H, Esaki M, Kosuge T (2008) Prognosis of perihilar cholangiocarcinoma: hilar bile duct cancer versus intrahepatic cholangiocarcinoma involving the hepatic hilus. Ann Surg Oncol 15(2):590–599CrossRefPubMed Sano T, Shimada K, Sakamoto Y, Ojima H, Esaki M, Kosuge T (2008) Prognosis of perihilar cholangiocarcinoma: hilar bile duct cancer versus intrahepatic cholangiocarcinoma involving the hepatic hilus. Ann Surg Oncol 15(2):590–599CrossRefPubMed
go back to reference Sasaki T, Isayama H, Nakai Y, Ito Y, Kogure H, Togawa O, Toda N, Yasuda I, Hasebe O, Maetani I, Sasahira N, Hirano K, Tsujino T, Tada M, Omata M (2009) Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol. doi:10.1007/s00280-009-1115-5 Sasaki T, Isayama H, Nakai Y, Ito Y, Kogure H, Togawa O, Toda N, Yasuda I, Hasebe O, Maetani I, Sasahira N, Hirano K, Tsujino T, Tada M, Omata M (2009) Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol. doi:10.​1007/​s00280-009-1115-5
go back to reference Schliess F, Kurz AK, Haussinger D (2000) Glucagon-induced expression of the MAP kinase phosphatase MKP-1 in rat hepatocytes. Gastroenterology 118(5):929–936CrossRefPubMed Schliess F, Kurz AK, Haussinger D (2000) Glucagon-induced expression of the MAP kinase phosphatase MKP-1 in rat hepatocytes. Gastroenterology 118(5):929–936CrossRefPubMed
go back to reference Shi YY, Small GW, Orlowski RZ (2006) Proteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer. Breast Cancer Res Treat 100(1):33–47CrossRefPubMed Shi YY, Small GW, Orlowski RZ (2006) Proteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer. Breast Cancer Res Treat 100(1):33–47CrossRefPubMed
go back to reference Small GW, Shi YY, Edmund NA, Somasundaram S, Moore DT, Orlowski RZ (2004) Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role. Mol Pharmacol 66(6):1478–1490CrossRefPubMed Small GW, Shi YY, Edmund NA, Somasundaram S, Moore DT, Orlowski RZ (2004) Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role. Mol Pharmacol 66(6):1478–1490CrossRefPubMed
go back to reference Small GW, Shi YY, Higgins LS, Orlowski RZ (2007) Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance. Cancer Res 67(9):4459–4466CrossRefPubMed Small GW, Shi YY, Higgins LS, Orlowski RZ (2007) Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance. Cancer Res 67(9):4459–4466CrossRefPubMed
go back to reference Sripa B, Leungwattanawanit S, Nitta T, Wongkham C, Bhudhisawasdi V, Puapairoj A, Sripa C, Miwa M (2005) Establishment and characterization of an opisthorchiasis-associated cholangiocarcinoma cell line (KKU-100). World J Gastroenterol 11(22):3392–3397PubMed Sripa B, Leungwattanawanit S, Nitta T, Wongkham C, Bhudhisawasdi V, Puapairoj A, Sripa C, Miwa M (2005) Establishment and characterization of an opisthorchiasis-associated cholangiocarcinoma cell line (KKU-100). World J Gastroenterol 11(22):3392–3397PubMed
go back to reference Starkey SJ, Grant AL, Hagan RM (2001) A rapid and transient synthesis of nitric oxide (NO) by a constitutively expressed type II NO synthase in the guinea-pig suprachiasmatic nucleus. Br J Pharmacol 134(5):1084–1092CrossRefPubMed Starkey SJ, Grant AL, Hagan RM (2001) A rapid and transient synthesis of nitric oxide (NO) by a constitutively expressed type II NO synthase in the guinea-pig suprachiasmatic nucleus. Br J Pharmacol 134(5):1084–1092CrossRefPubMed
go back to reference Takeuchi K, Shin-ya T, Nishio K, Ito F (2009) Mitogen-activated protein kinase phosphatase-1 modulated JNK activation is critical for apoptosis induced by inhibitor of epidermal growth factor receptor-tyrosine kinase. FEBS J 276(5):1255–1265CrossRefPubMed Takeuchi K, Shin-ya T, Nishio K, Ito F (2009) Mitogen-activated protein kinase phosphatase-1 modulated JNK activation is critical for apoptosis induced by inhibitor of epidermal growth factor receptor-tyrosine kinase. FEBS J 276(5):1255–1265CrossRefPubMed
go back to reference Vicent S, Garayoa M, Lopez-Picazo JM, Lozano MD, Toledo G, Thunnissen FB, Manzano RG, Montuenga LM (2004) Mitogen-activated protein kinase phosphatase-1 is overexpressed in non-small cell lung cancer and is an independent predictor of outcome in patients. Clin Cancer Res 10(11):3639–3649CrossRefPubMed Vicent S, Garayoa M, Lopez-Picazo JM, Lozano MD, Toledo G, Thunnissen FB, Manzano RG, Montuenga LM (2004) Mitogen-activated protein kinase phosphatase-1 is overexpressed in non-small cell lung cancer and is an independent predictor of outcome in patients. Clin Cancer Res 10(11):3639–3649CrossRefPubMed
go back to reference Wang J, Zhou JY, Zhang L, Wu GS (2009) Involvement of MKP-1 and Bcl-2 in acquired cisplatin resistance in ovarian cancer cells. Cell Cycle 8(19):3191–3198PubMed Wang J, Zhou JY, Zhang L, Wu GS (2009) Involvement of MKP-1 and Bcl-2 in acquired cisplatin resistance in ovarian cancer cells. Cell Cycle 8(19):3191–3198PubMed
go back to reference Widenmaier SB, Ao Z, Kim SJ, Warnock G, McIntosh CHS (2009) Suppression of p38 MAPK and JNK via Akt-mediated inhibition of apoptosis signal-regulating kinase 1 constitutes a core component of the beta-cell pro-survival effects of glucose-dependent insulinotropic polypeptide. J Biol Chem 284(44):30372–30382CrossRefPubMed Widenmaier SB, Ao Z, Kim SJ, Warnock G, McIntosh CHS (2009) Suppression of p38 MAPK and JNK via Akt-mediated inhibition of apoptosis signal-regulating kinase 1 constitutes a core component of the beta-cell pro-survival effects of glucose-dependent insulinotropic polypeptide. J Biol Chem 284(44):30372–30382CrossRefPubMed
go back to reference Wu GS (2007) Role of mitogen-activated protein kinase phosphatases (MKPs) in cancer. Cancer Metastasis Rev 26(3–4):579–585CrossRefPubMed Wu GS (2007) Role of mitogen-activated protein kinase phosphatases (MKPs) in cancer. Cancer Metastasis Rev 26(3–4):579–585CrossRefPubMed
go back to reference Yang WL, Zhang XC, Zhang DW, Tong BF (2007) Diagnosis and surgical treatment of hepatic hilar cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 6(6):631–635PubMed Yang WL, Zhang XC, Zhang DW, Tong BF (2007) Diagnosis and surgical treatment of hepatic hilar cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 6(6):631–635PubMed
go back to reference Yoon JH, Canbay AE, Werneburg NW, Lee SP, Gores GJ (2004) Oxysterols induce cyclooxygenase-2 expression in cholangiocytes: implications for biliary tract carcinogenesis. Hepatology 39(3):732–738CrossRefPubMed Yoon JH, Canbay AE, Werneburg NW, Lee SP, Gores GJ (2004) Oxysterols induce cyclooxygenase-2 expression in cholangiocytes: implications for biliary tract carcinogenesis. Hepatology 39(3):732–738CrossRefPubMed
Metadata
Title
Induction of MKP-1 prevents the cytotoxic effects of PI3K inhibition in hilar cholangiocarcinoma cells
Authors
Kawin Leelawat
Wandee Udomchaiprasertkul
Siriluck Narong
Surang Leelawat
Publication date
01-10-2010
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 10/2010
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-010-0811-1

Other articles of this Issue 10/2010

Journal of Cancer Research and Clinical Oncology 10/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.